134 related articles for article (PubMed ID: 24291969)
21. Long-term outcomes and prognostic factors in generalized myasthenia gravis.
Ozawa Y; Uzawa A; Yasuda M; Kojima Y; Onishi Y; Oda F; Kanai T; Himuro K; Kawaguchi N; Kuwabara S
J Neurol; 2021 Oct; 268(10):3781-3788. PubMed ID: 33774750
[TBL] [Abstract][Full Text] [Related]
22. [Calcineurin inhibitors and IVIg in the treatment of myasthenia gravis].
Nakane S
Rinsho Shinkeigaku; 2013; 53(11):1309-11. PubMed ID: 24291970
[TBL] [Abstract][Full Text] [Related]
23. Outcome of Myasthenia gravis treated with high-dose prednisolone and azathioprine: A single centre ambispective study from India.
Dube M; Sodani A; Chouksey D
Acta Neurol Taiwan; 2017 Sep; 26(3)():106-119. PubMed ID: 29468619
[TBL] [Abstract][Full Text] [Related]
24. Eculizumab improves fatigue in refractory generalized myasthenia gravis.
Andersen H; Mantegazza R; Wang JJ; O'Brien F; Patra K; Howard JF;
Qual Life Res; 2019 Aug; 28(8):2247-2254. PubMed ID: 30905021
[TBL] [Abstract][Full Text] [Related]
25. Low-dose glucocorticoid therapy complements the pituitary-adrenocortical system and reduces anxiety and insomnia in myasthenia gravis patients.
Ito S; Masuda M; Tanaka S; Takagi M; Tanaka C; Yamada N; Nakajima K; Akashi T; Hirano T; Utsumi H
Clin Neuropharmacol; 2012; 35(1):30-6. PubMed ID: 22240858
[TBL] [Abstract][Full Text] [Related]
26. Less is more, or almost as much: a 15-item quality-of-life instrument for myasthenia gravis.
Burns TM; Conaway MR; Cutter GR; Sanders DB;
Muscle Nerve; 2008 Aug; 38(2):957-63. PubMed ID: 18642357
[TBL] [Abstract][Full Text] [Related]
27. Long-term therapeutic efficacy and safety of low-dose tacrolimus (FK506) for myasthenia gravis.
Tada M; Shimohata T; Tada M; Oyake M; Igarashi S; Onodera O; Naruse S; Tanaka K; Tsuji S; Nishizawa M
J Neurol Sci; 2006 Aug; 247(1):17-20. PubMed ID: 16631797
[TBL] [Abstract][Full Text] [Related]
28. Quality of life in 188 patients with myasthenia gravis in China.
Yang Y; Zhang M; Guo J; Ma S; Fan L; Wang X; Li C; Guo P; Wang J; Li H; Li Z
Int J Neurosci; 2016; 126(5):455-62. PubMed ID: 26000922
[TBL] [Abstract][Full Text] [Related]
29. QMG and MG-ADL correlations: Study of eculizumab treatment of myasthenia gravis.
Howard JF; Freimer M; O'Brien F; Wang JJ; Collins SR; Kissel JT;
Muscle Nerve; 2017 Aug; 56(2):328-330. PubMed ID: 28010051
[TBL] [Abstract][Full Text] [Related]
30. Five-year follow-up with low-dose tacrolimus in patients with myasthenia gravis.
Minami N; Fujiki N; Doi S; Shima K; Niino M; Kikuchi S; Sasaki H
J Neurol Sci; 2011 Jan; 300(1-2):59-62. PubMed ID: 21035148
[TBL] [Abstract][Full Text] [Related]
31. [Titer of anti-muscle-specific receptor tyrosine kinase (MuSK) antibody correlated with symptomatic improvement in response to corticosteroid therapy in a patient with anti-MuSK antibody-positive myasthenia gravis: a case report].
Nakahama Y; Kawajiri M; Ochi M; Kohara K; Ohta K; Miki T
Rinsho Shinkeigaku; 2007 Jun; 47(6):356-8. PubMed ID: 17633110
[TBL] [Abstract][Full Text] [Related]
32. Validity and reliability of the Polish version of myasthenia gravis - Quality of life questionnaire - 15 item.
Rozmilowska I; Adamczyk-Sowa M; Pierzchala K; Czyzewski D
Neurol Neurochir Pol; 2017; 51(4):311-318. PubMed ID: 28579082
[TBL] [Abstract][Full Text] [Related]
33. Efficacy of high-dose intravenous methylprednisolone therapy for ocular myasthenia gravis.
Ozawa Y; Uzawa A; Kanai T; Oda F; Yasuda M; Kawaguchi N; Himuro K; Kuwabara S
J Neurol Sci; 2019 Jul; 402():12-15. PubMed ID: 31100651
[TBL] [Abstract][Full Text] [Related]
34. Long-Term Safety and Efficacy of Tacrolimus in Myasthenia Gravis.
Kim YH; Shin HY; Kim SM
Yonsei Med J; 2019 Jul; 60(7):633-639. PubMed ID: 31250577
[TBL] [Abstract][Full Text] [Related]
35. [Treatment of myasthenia gravis].
Wakata N
Rinsho Shinkeigaku; 1999 Dec; 39(12):1222-5. PubMed ID: 10791082
[TBL] [Abstract][Full Text] [Related]
36. Medication adherence in patients with myasthenia gravis in Brazil: a cross-sectional study.
Vitturi BK; Pellegrinelli A; Valerio BCO
Acta Neurol Belg; 2020 Feb; 120(1):83-89. PubMed ID: 31555980
[TBL] [Abstract][Full Text] [Related]
37. Factors associated with depressive state in patients with myasthenia gravis: a multicentre cross-sectional study.
Suzuki Y; Utsugisawa K; Suzuki S; Nagane Y; Masuda M; Kabasawa C; Shimizu Y; Utsumi H; Uchiyama S; Fujihara K; Suzuki N
BMJ Open; 2011; 1(2):e000313. PubMed ID: 22184587
[TBL] [Abstract][Full Text] [Related]
38. Low-Dose Medication and Long-Term Outcome in Myasthenia Gravis.
Salins S; Teter B; Kavak K; Wolfe GI; Silvestri NJ
J Clin Neuromuscul Dis; 2016 Dec; 18(2):61-66. PubMed ID: 27861217
[TBL] [Abstract][Full Text] [Related]
39. Gender differences in clinical outcomes in myasthenia gravis: A prospective cohort study.
Thomsen JLS; Vinge L; Harbo T; Andersen H
Muscle Nerve; 2021 Nov; 64(5):538-544. PubMed ID: 34036597
[TBL] [Abstract][Full Text] [Related]
40. Adequate tacrolimus concentration for myasthenia gravis treatment.
Kanai T; Uzawa A; Kawaguchi N; Himuro K; Oda F; Ozawa Y; Kuwabara S
Eur J Neurol; 2017 Feb; 24(2):270-275. PubMed ID: 28102047
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
